{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T08:46:44Z","timestamp":1696927604290},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can J Anesth\/J Can Anesth"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1007\/bf03022255","type":"journal-article","created":{"date-parts":[[2009,5,3]],"date-time":"2009-05-03T16:24:15Z","timestamp":1241367855000},"page":"S80-S88","source":"Crossref","is-referenced-by-count":3,"title":["Management of venous thromboembolism"],"prefix":"10.1007","volume":"53","author":[{"given":"Philippe de","family":"Moerloose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles Marc","family":"Samama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Motte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03022255_CR1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jama.1994.03510270069042","volume":"271","author":"KM Moser","year":"1994","unstructured":"Moser KM, Fedullo PF, LitteJohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep vein thrombosis. JAMA 1994; 271: 223\u20135.","journal-title":"JAMA"},{"issue":"3","key":"BF03022255_CR2","doi-asserted-by":"crossref","first-page":"401S","DOI":"10.1378\/chest.126.3_suppl.401S","volume":"126","author":"HR B\u00fcller","year":"2004","unstructured":"B\u00fcller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous throm- boembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic therapy. Chest 2004; 126 (suppl 3): 401S-8S.","journal-title":"Chest"},{"key":"BF03022255_CR3","doi-asserted-by":"crossref","first-page":"800","DOI":"10.7326\/0003-4819-130-10-199905180-00003","volume":"130","author":"MK Gould","year":"1999","unstructured":"Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800\u20139.","journal-title":"Ann Intern Med"},{"key":"BF03022255_CR4","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archinte.1988.00380060085018","volume":"148","author":"AP Wheeler","year":"1998","unstructured":"Wheeler AP, Jaquiss RD, Newman JH. Physician practices in the treatment of pulmonary embolism and deep venous thrombosis. Arch Intern Med 1998; 148: 1321\u20135.","journal-title":"Arch Intern Med"},{"key":"BF03022255_CR5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM199709043371002","volume":"337","author":"G Simonneau","year":"1997","unstructured":"Simonneau G, Sors H, Charbonnier B, ea al. A comparison of low-molecular-weight heparin with unfrac- tionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans \u013eEmbolie Pulmonaire. N Engl J Med 1997; 337: 663\u20139.","journal-title":"N Engl J Med"},{"key":"BF03022255_CR6","doi-asserted-by":"crossref","unstructured":"Anonymous. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 1997; 337: 657-62.","DOI":"10.1056\/NEJM199709043371001"},{"key":"BF03022255_CR7","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","volume":"126","author":"J Hirsh","year":"2004","unstructured":"Hirsh J, Raschke R. Heparin and low-molecular- weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S-203.","journal-title":"Chest"},{"key":"BF03022255_CR8","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1001\/archinte.160.15.2369","volume":"160","author":"M Zidane","year":"2000","unstructured":"Zidane M, Schram MT, Planken EW, ea al. Frequency of major hemorrhage in patients treated with unfrac- tionated intravenous heparin for deep venous thrombosis or pulmonary embolism: a study in routine clinical practice. Arch Intern Med 2000; 160: 2369\u201373.","journal-title":"Arch Intern Med"},{"key":"BF03022255_CR9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.1994.00420010073009","volume":"154","author":"MN Levine","year":"1994","unstructured":"Levine MN, Hirsh J, Gent M, ea al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49\u201356.","journal-title":"Arch Intern Med"},{"key":"BF03022255_CR10","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.164.10.1077","volume":"164","author":"P Prandoni","year":"2004","unstructured":"Prandoni P, Carnovali M, Marchiori A; Galilei Investigators. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med 2004; 164: 1077\u201383.","journal-title":"Arch Intern Med"},{"key":"BF03022255_CR11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1538-7933.2004.00648.x","volume":"2","author":"H Bounameaux","year":"2004","unstructured":"Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost 2004; 2: 551\u20134.","journal-title":"No. J Thromb Haemost"},{"key":"BF03022255_CR12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199603143341101","volume":"334","author":"M Levine","year":"1996","unstructured":"Levine M, Gent M, Hirsh J, ea al. A comparison of lowmolecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677\u201381.","journal-title":"N Engl J Med"},{"key":"BF03022255_CR13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1056\/NEJM199603143341102","volume":"334","author":"MM Koopman","year":"1996","unstructured":"Koopman MM, Prandoni P, Piovella F, ea al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334: 682\u20137.","journal-title":"N Engl J Med"},{"key":"BF03022255_CR14","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1055\/s-0037-1615089","volume":"79","author":"BA Charbonnier","year":"1998","unstructured":"Charbonnier BA, Fiessinger JN, Banga JD, Wenzel E, \u010fAzemar P, Sagnard L; on behalf of the FRAXODI group. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. Thromb Haemost 1998; 79: 897\u2013901.","journal-title":"Thromb Haemost"},{"key":"BF03022255_CR15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1055\/s-2001-17961","volume":"27","author":"B Boneu","year":"2001","unstructured":"Boneu B, de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Hemost 2001; 27: 519\u201322.","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"BF03022255_CR16","doi-asserted-by":"crossref","first-page":"204S","DOI":"10.1378\/chest.126.3_suppl.204S","volume":"126","author":"J Ansell","year":"2004","unstructured":"Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (suppl 3): 204S-33.","journal-title":"Chest"},{"issue":"3","key":"BF03022255_CR17","doi-asserted-by":"crossref","first-page":"287S","DOI":"10.1378\/chest.126.3_suppl.287S","volume":"126","author":"MN Levine","year":"2004","unstructured":"Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl 3): 287S-310.","journal-title":"Chest"},{"key":"BF03022255_CR18","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1056\/NEJM199506223322501","volume":"332","author":"S Schulman","year":"1995","unstructured":"Schulman S, Rhedin AS, Lindmarker P, ea al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332: 1661\u20135.","journal-title":"N Engl J Med"},{"key":"BF03022255_CR19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00001721-199607000-00001","volume":"7","author":"H Bounameaux","year":"1996","unstructured":"Bounameaux H, de Moerloose P, Sarasin FP. Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs. Blood Coagul Fibrinolysis 1996; 7: 507\u201314.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"BF03022255_CR20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199702063360601","volume":"336","author":"S Schulman","year":"1997","unstructured":"Schulman S, Granqvist S, Holmstr\u00f6m M, ea al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997; 336: 393\u20138.","journal-title":"N Engl J Med"},{"key":"BF03022255_CR21","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199903253401201","volume":"340","author":"C Kearon","year":"1999","unstructured":"Kearon C, Gent M, Hirsh J, ea al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901\u20137.","journal-title":"N Engl J Med"},{"key":"BF03022255_CR22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJM200107193450302","volume":"345","author":"G Agnelli","year":"2001","unstructured":"Agnelli G, Prandoni P, Santamaria MG, ea al.; for the Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001; 345: 165\u20139.","journal-title":"N Engl J Med"},{"key":"BF03022255_CR23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7326\/0003-4819-139-1-200307010-00008","volume":"139","author":"G Agnelli","year":"2003","unstructured":"Agnelli G, Prandoni P, Becattini C, ea al.; for the Warfarin Optimal Duration Italian Trial Investigators. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139: 19\u201325.","journal-title":"Ann Intern Med"},{"key":"BF03022255_CR24","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1161\/01.CIR.103.20.2453","volume":"103","author":"L Pinede","year":"2001","unstructured":"Pinede L, Ninet J, Duhaut P, ea al.; for the Investigators of the \u201cDur\u00e9e optimale du Traitement AntiVitamines K\u201d (DOTAVK). Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103: 2453\u201360.","journal-title":"Circulation"},{"key":"BF03022255_CR25","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","volume":"348","author":"PM Ridker","year":"2003","unstructured":"Ridker, PM, Goldhaber SZ, Danielson E, ea al.; for the PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425\u201334.","journal-title":"N Engl J Med"},{"key":"BF03022255_CR26","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa035422","volume":"349","author":"C Kearon","year":"2003","unstructured":"Kearon C, Ginsberg JS, Kovacs MJ, ea al.; for the Extended Low-Intensity Anticoagulation for Thrombo- Embolism (ELATE) Investigators. Comparison of low- intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631\u20139.","journal-title":"N Engl J Med"},{"key":"BF03022255_CR27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/01.CIR.0000079162.69615.0F","volume":"108","author":"G Palareti","year":"2003","unstructured":"Palareti G, Legnani C, Cosmi B, ea al. Predictive value of D-dimers test for recurrent venous thromboembo- lism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108: 313\u20138.","journal-title":"Circulation"},{"key":"BF03022255_CR28","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.290.8.1071","volume":"290","author":"S Eichinger","year":"2003","unstructured":"Eichinger S, Minar E, Bialonczyk C, ea al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003; 290: 1071\u20134.","journal-title":"JAMA"},{"key":"BF03022255_CR29","doi-asserted-by":"crossref","first-page":"955","DOI":"10.7326\/0003-4819-137-12-200212170-00008","volume":"137","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AW, Prins MH, ea al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 955\u201360.","journal-title":"Ann Intern Med"},{"key":"BF03022255_CR30","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","volume":"100","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AW, Piccioli A, ea al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484\u20138.","journal-title":"Blood"},{"key":"BF03022255_CR31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"AY Lee","year":"2003","unstructured":"Lee AY, Levine MN, Baker RI, ea al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146\u201353.","journal-title":"N Engl J Med"},{"key":"BF03022255_CR32","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","volume":"162","author":"G Meyer","year":"2002","unstructured":"Meyer G, Marjanovic Z, Valcke J, ea al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729\u201335.","journal-title":"Arch Intern Med"},{"key":"BF03022255_CR33","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMe038112","volume":"349","author":"HR Buller","year":"2003","unstructured":"Buller HR, Davidson BL, Decousus H, ea al.; for the Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695\u2013702.","journal-title":"N Engl J Med"},{"key":"BF03022255_CR34","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","volume":"140","author":"HR Buller","year":"2004","unstructured":"Buller HR, Davidson BL, Decousus H, ea al.; for the Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867\u201373.","journal-title":"Ann Intern Med"},{"key":"BF03022255_CR35","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2165\/00003088-200342080-00005","volume":"42","author":"E Bredberg","year":"2003","unstructured":"Bredberg E, Andersson TB, Frison L, ea al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 2003; 42: 765\u201377.","journal-title":"Clin Pharmacokinet"},{"key":"BF03022255_CR36","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","volume":"349","author":"S Schulman","year":"2003","unstructured":"Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H; THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 1713\u201321.","journal-title":"N Engl J Med"},{"key":"BF03022255_CR37","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.293.6.681","volume":"293","author":"JN Fiessinger","year":"2005","unstructured":"Fiessinger JN, Huisman MV, Davidson BL, ea al.; THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005; 293: 681\u20139.","journal-title":"JAMA"},{"key":"BF03022255_CR38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1055\/s-2001-14543","volume":"1","author":"E Bernardi","year":"2001","unstructured":"Bernardi E, Bagatella P, Frulla M, Simioni P, Prandoni P. Postthrombotic syndrome: incidence, prevention, and management. Semin Vasc Med 2001; 1: 71\u201380.","journal-title":"Semin Vasc Med"},{"key":"BF03022255_CR39","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(96)12215-7","volume":"349","author":"DP Brandjes","year":"1997","unstructured":"Brandjes DP, B\u00fcller HR, Heijboer H, ea al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759\u201362.","journal-title":"Lancet"},{"key":"BF03022255_CR40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.7326\/0003-4819-141-4-200408170-00004","volume":"141","author":"P Prandoni","year":"2004","unstructured":"Prandoni P, Lensing AW, Prins MH, ea al. Below-knee elastic compression stockings to prevent the post- thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004; 141: 249\u201356.","journal-title":"Ann Intern Med"},{"key":"BF03022255_CR41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-2001-14549","volume":"1","author":"R Verhaeghe","year":"2001","unstructured":"Verhaeghe R, Maleux G. Endovascular local thrombolytic therapy of iliofemoral and inferior caval vein thrombosis. Sem Vasc Med 2001; 1: 123\u20138.","journal-title":"Sem Vasc Med"},{"key":"BF03022255_CR42","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/01.CIR.96.3.716","volume":"96","author":"SZ Goldhaber","year":"1997","unstructured":"Goldhaber SZ. Pulmonary embolism thromboly- sis: broadening the paradigm for its administration. Circulation 1997; 96: 716\u20138.","journal-title":"Circulation"},{"key":"BF03022255_CR43","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/archinte.162.22.2521","volume":"162","author":"JE Dalen","year":"2002","unstructured":"Dalen JE. The uncertain role of thrombolytic therapy in the treatment of pulmonary embolism. Arch Intern Med 2002; 162: 2521\u20133.","journal-title":"Arch Intern Med"},{"key":"BF03022255_CR44","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1161\/01.CIR.96.3.882","volume":"96","author":"S Konstantinides","year":"1997","unstructured":"Konstantinides S, Geibel A, Olschewski M, ea al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation 1997; 96: 882\u20138.","journal-title":"Circulation"},{"key":"BF03022255_CR45","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa021274","volume":"347","author":"S Konstantinides","year":"2002","unstructured":"Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W; Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347: 1143\u201350.","journal-title":"N Engl J Med"},{"key":"BF03022255_CR46","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1161\/01.CIR.0000012526.21603.25","volume":"105","author":"L Aklog","year":"2002","unstructured":"Aklog L, Williams CS, Byrne JG, Goldhaber SZ. Acute pulmonary embolectomy: a contemporary approach. Circulation 2002; 105: 1416\u20139.","journal-title":"Circulation"},{"key":"BF03022255_CR47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM199802123380701","volume":"338","author":"H Decousus","year":"1998","unstructured":"Decousus H, Leizorovicz A, Parent F, ea al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque \u010fEmbolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998; 338: 409\u201315.","journal-title":"N Engl J Med"}],"container-title":["Canadian Journal of Anesthesia\/Journal canadien d'anesth\u00e9sie"],"original-title":[],"language":"fr","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03022255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03022255\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03022255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T20:12:43Z","timestamp":1558555963000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03022255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":47,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["BF03022255"],"URL":"https:\/\/doi.org\/10.1007\/bf03022255","relation":{},"ISSN":["0832-610X","1496-8975"],"issn-type":[{"value":"0832-610X","type":"print"},{"value":"1496-8975","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}